Overview

A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the efficacy of at least 1 dose of tapentadol IR 50 mg and/or 75 mg versus placebo using the sum of pain intensity difference at 48 hours (SPID48) to measure analgesic effect in Korean patients with acute pain following bunionectomy.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Tapentadol